Over-expression of the ERBB2 gene or HER2 protein occurs in 15–20% of all invasive breast cancers and has an important bearing on prognosis, as majority of HER2-positive tumors are associated with a more aggressive clinical course and typically a poor outcome [2]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.